Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1209-1211, 2003; 10.1373/49.7.1209
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trapé, J.
Right arrow Articles by Roca, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trapé, J.
Right arrow Articles by Roca, A.
Related Collections
Right arrow General Clinical Chemistry
(Clinical Chemistry. 2003;49:1209-1211.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Reference Change Value for {alpha}-Fetoprotein and Its Application in Early Detection of Hepatocellular Carcinoma in Patients with Hepatic Disease

Jaume Trapé1,a, Josep M. Botargues2, Francesc Porta2, Carmen Ricós4, Josep M. Badal3, Ramon Salinas1, Maria Sala1 and Angels Roca1

1 Laboratori d’Analisis Clíniques,
2 Secció de Gastroenterologia, and
3 Servei d’Anatomia Patologica, Hospital Sant Joan de Déu, Althaia Xarxa Assistencial de Manresa, Dr. Joan Soler, s/n 08243 Manresa, Barcelona, Spain

4 Laboratoris Clínics Hospital Vall d’Hebron, 08035. Barcelona, Spain

aauthor for correspondence: fax 34-93-8743859, e-mail hgmlaboratorio@aehh.org

The first 300 words of the full text of this article appear below.

Hepatocellular carcinoma (HCC) is one of the most frequent types of cancer worldwide, with an incidence of 150 cases per 100 000 inhabitants per year in Asia and Africa and ~5 cases per 100 000 per year in Europe, North America, and Australia (1). HCC can occur in healthy livers, but it is generally associated with hepatic disease. Cirrhosis is the most important risk factor for its development (2).

Many studies have been dedicated to the early detection of HCC in patients with chronic liver disease (CLD), based on semiannual or annual measurement of serum {alpha}-fetoprotein (AFP) and ultrasound study of the liver. The interpretation of AFP results usually involves comparison with a fixed cutoff ranging from 20 to 500 µg/L, with sensitivities ranging from 33% to 64% (3)(4)(5). Another approach would be to assess changes in consecutive results from the same patient.

To establish a criterion for dynamic assessment of a specific biological constituent, the first step is to define when a difference between two consecutive results indicates a change in a patient’s health status. The most widely accepted approach for this purpose is the so-called reference change value (RCV), a concept described by Harris and Brown (6). Using serial analytic results from the same individual for a specific constituent, it is possible to calculate the RCV that defines how large a difference between two consecutive determinations is statistically significant (P <0.05). The RCV encompasses both biological and analytical variation.

The RCV has been determined for various constituents in healthy persons and in some pathologies (7)(8)(9)(10)(11)(12)(13). In diseases that can modify the homeostatic set point and the degree of fluctuation of a . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
A. K. Aarsand, P. H. Petersen, and S. Sandberg
Estimation and Application of Biological Variation of Urinary {delta}-Aminolevulinic Acid and Porphobilinogen in Healthy Individuals and in Patients with Acute Intermittent Porphyria.
Clin. Chem., April 1, 2006; 52(4): 650 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Comin-Anduix, A. Gualberto, J. A. Glaspy, E. Seja, M. Ontiveros, D. L. Reardon, R. Renteria, B. Englahner, J. S. Economou, J. Gomez-Navarro, et al.
Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays
Clin. Cancer Res., January 1, 2006; 12(1): 107 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Trape, J. Perez de Olaguer, J. Buxo, and L. Lopez
Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients with Non-Small Cell Lung Cancer
Clin. Chem., January 1, 2005; 51(1): 219 - 222.
[Full Text] [PDF]

eLetters:

Read all eLetters

Alpha fetoprotein-linked immunoglobulin complex in blood
Toshio Okazaki, et al.
Clinical Chemistry Online, 5 Oct 2004 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.